Reuters logo
2 months ago
BRIEF-Myriad Genetics announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test
June 2, 2017 / 11:31 AM / 2 months ago

BRIEF-Myriad Genetics announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test

June 2 (Reuters) - Myriad Genetics Inc

* Myriad Genetics Inc announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test

* Myriad Genetics - ‍key findings are that more than 50 percent of mutations identified were in patients who would not meet current testing guidelines​

* Myriad Genetics-34 percent mutations identified in unexpected genes, confirming use of multi-gene panel testing to improve hereditary cancer-risk assessment Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below